Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tivity Health (TVTY – Research Report) and LumiraDx (LMDX – Research Report).
Tivity Health (TVTY)
In a report released today, Jailendra Singh from Credit Suisse maintained a Hold rating on Tivity Health, with a price target of $31.00. The company’s shares closed last Friday at $30.69, close to its 52-week high of $30.85.
According to TipRanks.com, Singh is ranked 0 out of 5 stars with an average return of
Tivity Health has an analyst consensus of Moderate Buy, with a price target consensus of $32.00.
See Insiders’ Hot Stocks on TipRanks >>
In a report released today, Andrew Cooper from Raymond James maintained a Buy rating on LumiraDx, with a price target of $9.00. The company’s shares closed last Friday at $6.08, close to its 52-week low of $5.91.
According to TipRanks.com, Cooper is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
LumiraDx has an analyst consensus of Moderate Buy, with a price target consensus of $9.50, representing a 55.0% upside. In a report released today, BTIG also maintained a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TVTY:
- Credit Suisse Sticks to Their Hold Rating for MeridianLink (MLNK)
- VSE (VSEC) Receives a Rating Update from a Top Analyst
- Raymond James Believes Kite Realty Group (KRG) Still Has Room to Grow
- Credit Suisse Sticks to Its Hold Rating for Vital Farms (VITL)
- Raymond James Keeps Their Buy Rating on Essential Properties Realty (EPRT)